Informa Australia is part of the Informa Connect Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.
[tweetmeme source= “informa_oz” only_single=false]
Melbourne – 28th September 2010 – MedTRACK, a market leading database of private and public biomedical companies, reports that the number of transactions in the Asia-Pacific region is on pace to rebound by 15% in 2010.
Sarah Terry, President of MedTRACK comments:
To be a company in Asia-Pacific region is really promising. Indeed, the number of venture financings is bucking the trend and royalty rates for early to mid-stage products are nearly twice as high as anywhere else in the world.
Read more below.
For more information on the data contained herein, please contact Delphine Jersier on +613 9601 6725 or djersier@datamonitor.com
_____________________________________
To be a company in Asia-Pacific region is really promising. Indeed, the number of venture financings is bucking the trend and royalty rates for early to mid-stage products are nearly twice as high as anywhere else in the world.
“While venture financing deals have dropped steadily since 2006, the number of transactions in the Asia-Pacific region is on pace to rebound by 15% in 2010” according to Sarah Terry from MedTRACK, a market leading biomedical database.
In 2009 there were only 53 venture finance deals, already this year there have been 49. This is bucking the trend seen in other regions where venture financings are still in decline. “Indeed, the number of venture financing transactions in North America and Europe are forecast to drop another 30% and 15% respectively this year compared to last year, to roughly 350 in North America and 240 in Europe”, added Terry, President of MedTRACK.
Companies in the Asia-Pacific region are also winners when it comes to royalty rates. Royalty rates for products in Phase I and Phase II are nearly twice as high as in the other regions, with rates around 20%. And while the rates are not nearly as disparate in Phase III, it certainly bodes well for the 307 APAC companies with products in development.
Informa Connect Australia is the nation's leading event organiser. Our events comprise of large scale exhibitions, industry conferences and highly specialised corporate training.
